Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Synta Pharmaceuticals, Corp. |
---|---|
Information provided by: | Synta Pharmaceuticals, Corp. |
ClinicalTrials.gov Identifier: | NCT00808418 |
This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: Elesclomol Sodium Drug: Docetaxel |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1/2 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC) |
Estimated Enrollment: | 34 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Cohort: Experimental |
Drug: Elesclomol Sodium
Chemotherapy agent
Drug: Docetaxel
Chemotherapy agent
|
This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
United States, California | |
Pacific Coast Hematology/Oncology Medical Group | |
Fountain Valley, California, United States, 92708 | |
United States, Maryland | |
Mayo Clinic | |
Rochester, Maryland, United States, 55905 | |
United States, North Dakota | |
Mid Dakota Clinic | |
Bismarck, North Dakota, United States, 58501 | |
United States, Texas | |
University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development | |
San Antonio, Texas, United States, 78229 | |
United States, Wisconsin | |
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center | |
Madison, Wisconsin, United States, 53792 |
Responsible Party: | Synta Pharmaceuticals ( David Hynds, Clinical Trials Manager ) |
Study ID Numbers: | 4783-12 |
Study First Received: | December 12, 2008 |
Last Updated: | March 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00808418 History of Changes |
Health Authority: | United States: Food and Drug Administration |
prostate cancer metastatic castration refractory |
elesclomol sodium docetaxel prednisone |
Anti-Inflammatory Agents Prednisone Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents, Hormonal Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists |
Urogenital Neoplasms Genital Diseases, Male Glucocorticoids Hormones Docetaxel Prostatic Neoplasms |
Anti-Inflammatory Agents Prednisone Antineoplastic Agents, Hormonal Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Urogenital Neoplasms |
Genital Diseases, Male Glucocorticoids Hormones Pharmacologic Actions Docetaxel Neoplasms Neoplasms by Site Therapeutic Uses Prostatic Neoplasms |